News >

Brigatinib Approved in Europe for Frontline ALK+ NSCLC

Jason M. Broderick @jasoncology
Published: Monday, Apr 06, 2020

Sanjay Popat, BSc MBBS FRCP PhD, consultant medical oncologist at The Royal Marsden NHS Foundation Trust, Seattle Cancer Care Alliance

Sanjay Popat, BSc MBBS FRCP PhD

The European Commission has approved brigatinib (Alunbrig) for the first-line treatment of patients with  ALK-positive metastatic non–small cell lung cancer (NSCLC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication